Coronavirus disease 2019 (COVID-19) has rapidly spread around the world in the past 3 months and has now become a global public health crisis. The mortality of COVID-19 in some European cities exceeds 11%, and the fatality rate is up to 61.5% in critical patients, especially in mechanically ventilated patients \[[@CR1]\]. Once mild to moderate patients progress to critical illness, the incidence of septic shock, intubation, and myocardial injury increases significantly. Mechanical ventilation patients need more sedative, analgesic, and neuromuscular blocker drugs, which will affect the patient's hemodynamic status and airway expectoration ability \[[@CR2]\]. Previous studies have confirmed that high-flow nasal cannula (HFNC) can reduce the endotracheal intubation rate and mortality in patients with respiratory failure \[[@CR3]\]. However, this therapy of COVID-19 cannot improve the pathophysiology of ventilation-perfusion defects and atelectasis, which can be proved by autopsies, i.e., small airways are blocked by mucus plugs \[[@CR4]\]. Awake prone position could improve the mismatch of ventilation-perfusion and open the atelectatic lungs by adequate sputum drainage. So far, the role of early awake prone position (PP) combined with HFNC therapy in the treatment of severe COVID-19 has not been reported. So, we conducted a retrospective observation study in three hospitals in Wuhu and Maanshan cities in Anhui Province.

From January 1 to April 2, 2020, 79 patients with coronavirus infection were screened. Ten was severe and all of them received early awake PP combined with HFNC treatment (Table [1](#Tab1){ref-type="table"}). COVID-19 was diagnosed using sputum or throat swab determined by real-time reverse transcription polymerase chain reaction (RT-PCR) assay. The severity of disease was graded according to the Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (trial version 5). The target time of prone positioning is more than 16 h per day and can be appropriately shortened according to the patient's tolerance. Target SpO~2~ was more than 90% of adult non-pregnant patients (Fig. [1](#Fig1){ref-type="fig"}a). Table 1Clinical characteristics and outcomes of COVID patients treated by prone position combine with HFNCCase no.GenderAge (years)ComorbidityImagine featuresTime from illness onset to hospitalizationBaseline PF (onset of HFNC) (mmHg)WBC (× 10^9^/L)L (× 10^9^/L)PCT (ng/ml)CRP (mg/L)D-dimer (mg/L)IntubationLength of stay (days)Outcome1Male54Bilateral lobes, GGO and consolidation10156.85.20.80.1111.22.4No18Survivor2Female56DMBilateral lobes, GGO5169.25.41.00.38.21.0No19Survivor3Male47DM, HBPBilateral pulmonary infiltration10123.69.61.00.284.00.2No11Survivor4Female65Bilateral lobes, GGO6117.76.60.40.297.33.0No11Survivor5Female51HBPBilateral pulmonary infiltration10205.86.20.60.1110.20.6No11Survivor6Male43Bilateral lobes, GGO and consolidation6188.82.20.8\< 0.127.71.2No15Survivor7Female48HBPBilateral lobes, GGO and consolidation989.14.70.5\< 0.147.40.9No30Survivor8Female51Bilateral lobes, GGO and consolidation5155.59.52.0\< 0.168.30.4No22Survivor9Male56HBPBilateral lobes, GGO and consolidation6227.83.61.1\< 0.115.32.3No19Survivor10Male31Bilateral lobes, GGO and consolidation1134.74.21.40.29.51.9No21SurvivorFig. 1**a** The protocol treatment of severe COVID-19 patients. **b** The change of PaO~2~/FiO~2~ in the first 3 days between onset of HFNC and 4--6 h after PP therapy in severe COVID-19 patients

All the severe patients, with PF \< 300 mmHg, developed mild respiratory alkalosis and no alkalemia at the beginning of HFNC treatment. After PP, compared with the baseline, the median PaCO~2~ increases slightly \[32.3 (29.3--34.0) vs. 29.7 (28.0--32.0), *p* \< 0.001\]. The median PaO~2~/FiO2 (PF) was elevated significantly after PP (Fig. [1](#Fig1){ref-type="fig"}b). None of the patients progressed to critical condition or needed endotracheal intubation.

When the condition of patients with severe coronavirus deteriorated rapidly and the mortality rate was unacceptably high \[[@CR1]\], we then put forward a concept "reduce the proportion of severe COVID-19 conversion to critical illness," based on the experience summarized during the treatment of COVID-19 in Anhui, China. Early awake PP combined with HFNC therapy was one of the most important strategies to avoid intubation and reduce the requirement for medical staff. A previous study reported that early application of PP with HFNC therapy, especially in patients with moderate ARDS, may help avoid intubation but not in the several ARDS group \[[@CR5]\]. However, in non-infected severe ARDS patients with a PF \< 100 mmHg, 5 of 6 patients avoided intubation. In our research, the lowest P/F ratio was 89 mmHg, and the patient was successfully discharged without invasive mechanical ventilation. The main reason for the patients' intolerance of PP is discomfort, anxiety \[[@CR6]\], and the inability to change position. Our strategy was psychological care and a slight change of position every 2 h.

Compared to non-invasive ventilation (NIV), patients felt more comfortable when using HFNC therapy, and the demand for medical staff was reduced. Awake PP combined with HFNC therapy could be used safely and effectively in severe COVID-19 patients, and it may reduce the conversion to critical illness and the need for tracheal intubation.
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